Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | USP5 | P45974 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691985 | 1.00 | FFAR1 (0.59) | FFAR1POLBSMN1; SMN2TDP1ACHE | |
| SCHEMBL11332403 | 0.88 | FFAR1 (0.62) | FFAR1POLBSMN1; SMN2ACHEALDH1A1 | |
| SCHEMBL12883299 | 0.84 | ACHE (0.46) | FFAR1POLBSMN1; SMN2TDP1ACHE | |
| SCHEMBL27953749 | 0.82 | FFAR1 (0.41) | FFAR1POLBSMN1; SMN2TDP1ACHE | |
| SCHEMBL25152959 | 0.82 | ACHE (0.67) | FFAR1POLBACHEALDH1A1TSHR | |
| SCHEMBL7559049 | 0.82 | ACHE (0.67) | FFAR1POLBACHEALDH1A1TSHR | |
| SCHEMBL12883165 | 0.82 | ACHE (0.67) | FFAR1POLBACHEALDH1A1TSHR | |
| SCHEMBL31522488 | 0.82 | FFAR1 (0.61) | FFAR1TDP1ACHEALDH1A1TSHR | |
| SCHEMBL1162528 | 0.82 | FFAR1 (0.61) | FFAR1TDP1ACHEALDH1A1TSHR | |
| SCHEMBL13140496 | 0.82 | FFAR1 (0.61) | FFAR1TDP1ACHEALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-1153017-B1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1177186-B1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | AVENTIS PHARMA LTD (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-6620832-B2 | Inhibitor of alpha 4 beta 1 mediated cell adhesion; treatment for asthma and antiinflammatory | AVENTIS PHARMA LTD. (GB) | 2003-09-16 | — | — | US | disclosed |
| US-6593354-B2 | Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 | AVENTIS PHARMA LIMITED (GB) | 2003-07-15 | — | — | US | disclosed |
| US-20020137782-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-09-26 | — | — | US | disclosed |
| US-20020082255-A1 | Substituted ureas | AVENTIS PHARMA LIMITED (GB) | 2002-06-27 | — | — | US | disclosed |
| EP-1177186-A1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | Aventis Pharma Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| EP-1153017-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | Aventis Pharma Limited (GB) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000068223-A1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000049005-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LIMITED (GB) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | FFAR1 1037/4885POLB 3981/4885SMN1; SMN2 4705/4885 |
| US-20020082255-A1 | Substituted ureas | VCAM1, ITGA1, ITGB1 | FFAR1 99/4885POLB 3769/4885SMN1; SMN2 3307/4885 |
| US-20020137782-A1 | Substituted bicyclic compounds | ITGA1, VCAM1, ITGB1 | FFAR1 175/4885POLB 3796/4885SMN1; SMN2 2427/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | FFAR1 1037/4885POLB 3981/4885SMN1; SMN2 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.